JAK inhibitors for asthma
| Autor: | Steve N. Georas, Patrick Donohue, Michael E. Wechsler, Margaret Connolly |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Thymic stromal lymphopoietin
business.industry medicine.medical_treatment Drug Administration Routes Immunology JAK-STAT signaling pathway Atopic dermatitis Disease medicine.disease Article Asthma respiratory tract diseases STAT Transcription Factors medicine STAT protein Immunology and Allergy Animals Humans Janus Kinase Inhibitors Disease-modifying antirheumatic drug business Janus kinase Janus Kinases |
| Zdroj: | J Allergy Clin Immunol |
| Popis: | Asthma is an inflammatory disease of the airways characterized by intermittent episodes of wheezing, chest tightness, and cough. Many of the inflammatory pathways implicated in asthma involve cytokines and growth factors that activate Janus kinases (JAKs). The discovery of the JAK/signal transducer and activator of transcription (STAT) signaling pathway was a major breakthrough that revolutionized our understanding of cell growth and differentiation. JAK inhibitors are under active investigation for immune and inflammatory diseases, and they have demonstrated clinical efficacy in diseases such as rheumatoid arthritis and atopic dermatitis. Substantial preclinical data support the idea that inhibiting JAKs will ameliorate airway inflammation and hyperreactivity in asthma. Here, we review the rationale for use of JAK inhibitors in different asthma endotypes as well as the preclinical and early clinical evidence supporting such use. We review preclinical data from the use of systemic and inhaled JAK inhibitors in animal models of asthma and safety data based on the use of JAK inhibitors in other diseases. We conclude that JAK inhibitors have the potential to usher in a new era of anti-inflammatory treatment for asthma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|